TwoFour appoints Sherry Isenberg MD, North American sales

Source: TwoFour

TwoFour, provider of treasury, FX and cash management solutions, today announced that Sherry Isenberg has joined the firm as managing director of North American sales.

This newly created role reflects the strong demand that TwoFour is seeing for its solutions and its anticipated growth in this region. TwoFour has experienced year-on-year growth since its inception and Isenberg will be responsible for continuing to drive the company's expansion strategy.

Isenberg has more than 15 years experience in the treasury and technology arena, having held a number of senior sales positions. Most recently with Fiserv Corporation, she was vice president for North American sales & client relationship management and previously head of the financial services vertical at Hyperion (acquired by Oracle in 2007). This entailed delivering technology solutions to some of the largest global financial services firms, corporate treasury departments, asset management and broker-dealer firms.

"As the FX, treasury and cash management space continues to evolve, with new impending regulations and a stronger focus on risk management, this is an evolving and fast-paced area to be involved in," said Sherry Isenberg, managing director of North American sales, TwoFour. "I am delighted to be joining TwoFour and keen to build on the momentum and growth the organisation is experiencing in North America".

Prior to moving into the software technology market, Isenberg spent more than 13 years at Arizona's largest energy services company, where she held several positions including senior financial analyst on the institutional side of corporate treasury and cash management. She has a Bachelors degree in Finance from Arizona State University and an MBA in Finance from Western International University.

Steven Davis, CEO of TwoFour commented: "We are very excited to have an executive of Sherry's calibre and experience join our team; this is a clear milestone in TwoFour's development."

Comments: (0)

sponsored